By: IPP Bureau
Last updated : November 02, 2025 6:12 pm
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Bristol Myers Squibb announced its financial results for the third quarter of 2025, reflecting continued strength across its Growth Portfolio, robust pipeline progress, and strategic business execution.
Total revenues for the quarter reached $12.2 billion, representing a 3 per cent increase (or 2 per cent at constant exchange rates) compared to the same period last year. The company’s Growth Portfolio revenues rose 18 per cent (or 17 per cent Ex-FX) to $6.9 billion, driven by strong performance from key products including Opdivo, Reblozyl, Camzyos, and Breyanzi.
Meanwhile, the Legacy Portfolio generated $5.4 billion in revenues, a 12 per cent decline, primarily reflecting expected generic competition across several products, partially offset by continued demand for Eliquis.
Geographically, U.S. revenues grew 1 per cent to $8.3 billion, while international revenues increased 6 per cent (or 3 per cent Ex-FX) to $3.9 billion.
GAAP earnings per share (EPS) for the third quarter were $1.08, and non-GAAP EPS were $1.63. Both figures include a net impact of $(0.20) per share due to acquired in-process research and development (IPRD) charges and licensing income.
Given the company’s strong year-to-date performance, Bristol Myers Squibb has raised its full-year 2025 revenue guidance to a range of approximately $47.5 billion to $48.0 billion and updated its non-GAAP EPS guidance to $6.40 to $6.60, inclusive of an $(0.80) per share net impact from acquired IPRD charges and licensing income.
“We delivered strong results this quarter as a result of continued execution across the business and ongoing Growth Portfolio momentum,” said Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer of Bristol Myers Squibb. “We are focused on building for the future by accelerating innovation, advancing our pipeline, staying agile, and delivering more transformational medicines to more patients.”
Bristol Myers Squibb’s continued investment in innovation and strategic partnerships has positioned the company for sustainable growth, with a pipeline designed to deliver long-term value to patients, healthcare providers, and shareholders.